Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

References

• Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449–86. doi:10.1128/CMR.00083-15. PMID:27029594.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global and regional immunization profile, 2016. Available from: http://www.who.int/immunization/monitoring_surveillance/data/gs_gloprofile.pdf?ua=1; [accessed July 2017].
   Google Scholar
• Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209(7):978–81. doi:10.1093/infdis/jiu001. PMID:24626532.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Pertussis cases by year (1922-2015) Updated January 2017. Available from: https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html; [accessed July 2017].
   Google Scholar
• Centers for Disease Control. National Center for Immunization and Respiratory Diseases. 2016 Provisional pertussis surveillance report. January 6, 2017. Available from: https://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2016-provisional.pdf; [accessed November 2017].
   Google Scholar
• Barret AS, Ryan A, Breslin A, Cullen L, Murray A, Grogan J, Bourke S, Cotter S. Pertussis outbreak in northwest Ireland, January – June 2010. Euro Surveill. 2010;15(35). PMID:20822735.
   PubMedGoogle Scholar
• Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, Lan R. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008–2010. J Infect Dis. 2012;205(8):1220–4. doi:10.1093/infdis/jis178. PMID:22416243.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Doemland M, Bettinger JA, Scheifele DW, Halperin SA, Impact Investigators, Waters V, Kandola K. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J. 2009;28(6):521–8. doi:10.1097/INF.0b013e318199d2fc. PMID:19436236.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Notes from the field: Pertussis-California, January-June 2010. MMWR. 2010;59(26):817.
   Google Scholar
• Lavine JS, Bjornstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012;30(3):544–51. doi:10.1016/j.vaccine.2011.11.065. PMID:22119924.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Pertussis. In: ECDC. Annual epidemiological report for 2015. Stockholm: ECDC; 2017.
   Google Scholar
• Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect. 2014;142(4):672–84. doi:10.1017/S0950268812003093. PMID:23324361.
   PubMed Web of Science ®Google Scholar
• Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis. 2014;209(12):1981–8. doi:10.1093/infdis/jiu030. PMID:24443545.
   PubMed Web of Science ®Google Scholar
• Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis. 2015;73(8):ftv057. doi:10.1093/femspd/ftv057. PMID:26253079.
   PubMed Web of Science ®Google Scholar
• Choi YH, Campbell H, Amirthalingam G, van Hoek AJ, Miller E. Investigating the pertussis resurgence in England and Wales, and options for future control. BMC Med. 2016;14(1):121. doi:10.1186/s12916-016-0665-8. PMID:27580649.
   PubMed Web of Science ®Google Scholar
• Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–60. PMID:7031583.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Frith K, Snelling TL, Grimwood K, McIntyre PB, Lambert SB. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Expert Rev Vaccines. 2014;13(9):1081–106. doi:10.1586/14760584.2014.944167. PMID:25093268.
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61. doi:10.1097/01.inf.0000160914.59160.41. PMID:15876927.
   PubMedGoogle Scholar
• Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1–34.
   Google Scholar
• Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(2):1–64. PMID:21293327.
   Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. MMWR. 2011;60(41):1424–6. PMID:22012116.
   PubMedGoogle Scholar
• Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine. 2003;21(17-18):2015–21. doi:10.1016/S0264-410X(02)00777-6. PMID:12706691.
   PubMed Web of Science ®Google Scholar
• Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24(5 Suppl):S10–8. doi:10.1097/01.inf.0000160708.43944.99. PMID:15876918.
   PubMedGoogle Scholar
• Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135(6):981–9. doi:10.1542/peds.2014-3358. PMID:25941309.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap effectiveness in adolescents. Pediatrics. 2016;137(3):e20153326. doi:10.1542/peds.2015-3326. PMID:26908667.
   PubMed Web of Science ®Google Scholar
• Koepke R, Eickhoff JC, Ayele RA, Petit AB, Schauer SL, Hopfensperger DJ, Conway JH, Davis JP. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942–53. doi:10.1093/infdis/jiu322. PMID:24903664.
   PubMed Web of Science ®Google Scholar
• Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine. 2010;29(1):45–50. doi:10.1016/j.vaccine.2010.10.025. PMID:20974302.
   PubMed Web of Science ®Google Scholar
• Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010;51(6):656–62. doi:10.1086/655825. PMID:20704493.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084–93. doi:10.1542/peds.2005-1759. PMID:16585302.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, von Konig CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275(1):37–41. doi:10.1001/jama.1996.03530250041024. PMID:8531284.
   PubMed Web of Science ®Google Scholar
• Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29(5):1017–22. doi:10.1016/j.vaccine.2010.11.057. PMID:21134450.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, Schult R, Folkens J, Rauh W, Bogaerts H, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129(5):695–701. doi:10.1016/S0022-3476(96)70152-X. PMID:8917236.
   PubMed Web of Science ®Google Scholar
• Vandermeulen C, Theeten H, Rathi N, Kuriyakose S, Han HH, Sokal E, Hoppenbrouwers K, Van Damme P. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. Vaccine. 2015;33(26):3026–34. doi:10.1016/j.vaccine.2014.10.049. PMID:25613716.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization. Drugs. 2012;72(13):1765–91. doi:10.2165/11209630-000000000-00000. PMID:22931522.
   PubMed Web of Science ®Google Scholar
• Theeten H, Van Damme P, Hoppenbrouwers K, Vandermeulen C, Leback E, Sokal EM, Wolter J, Schuerman L. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine. 2005;23(12):1515–21. doi:10.1016/j.vaccine.2004.08.002. PMID:15670888.
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, Chen Z, Slifka MK. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: A cross-sectional analysis. Clin Infect Dis. 2016;62(9):1111–8. doi:10.1093/cid/ciw066. PMID:27060790.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivee L, Langley JM, McNeil SA, Dobson S, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012;30(5):974–82. doi:10.1016/j.vaccine.2011.11.035. PMID:22115634.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. Guidance for industry. July 2015. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm386366.pdf; [accessed February 2018].
   Google Scholar
• Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11(2):137–44. doi:10.1016/S0092-1157(83)80038-9. PMID:6345548.
   PubMedGoogle Scholar
• Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol. 1984;20(4):772–4. PMID:6386879.
   PubMed Web of Science ®Google Scholar
• Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods. 1987;103(2):189–94. doi:10.1016/0022-1759(87)90289-4. PMID:3668258.
   PubMed Web of Science ®Google Scholar
• Granstrom M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol. 1987;6(1):18–21. doi:10.1007/BF02097184. PMID:2883004.
   PubMedGoogle Scholar
• Zou GY, Donner A. Construction of confidence limits about effect measures: a general approach. Stat Med. 2008;27(10):1693–702. doi:10.1002/sim.3095. PMID:17960596.
   PubMed Web of Science ®Google Scholar